Skip to content

Peptides, hormones and pipeline drugs

CagriSema

CagriSema is an investigational once-weekly injection from Novo Nordisk that combines cagrilintide, an amylin analog, with semaglutide in one pen.

Clinician review pending Updated Peptides, hormones and pipeline drugs
DefinitionCagriSema is an investigational once-weekly injection from Novo Nordisk that combines cagrilintide, an amylin analog, with semaglutide in one pen.

What it means

CagriSema pairs two separate molecules: cagrilintide, which acts on amylin receptors, and semaglutide, the GLP-1 receptor agonist in Wegovy. The goal is to reduce appetite through two hormone pathways at once.

In the REDEFINE 1 trial, published in NEJM in 2025, adults with obesity or overweight without diabetes lost about 20.4% of body weight on average at 68 weeks on the combination, compared with about 3.0% on placebo. Most side effects were stomach-related and mild to moderate.

Novo Nordisk filed CagriSema with the FDA in late 2025 for chronic weight management. It was not FDA-approved at our last review, so check FDA.gov or the maker for the current status.

Because it contains semaglutide, CagriSema would be expected to carry the same class warnings, including the boxed warning about thyroid C-cell tumors. Its final label would set those details.

Why it matters

CagriSema could be the first amylin-plus-GLP-1 medicine for weight, so its FDA decision affects future treatment choices.

Related tools

GLP-1 weight-loss projection

Expected loss by drug, dose and week, from trial data

Open

Related terms

CagrilintideSemaglutideAmylinDual agonist

Sources

  1. REDEFINE 1 trial (NEJM, 2025)

Clinician review pending. Drafted from primary sources and waiting for sign-off by a licensed clinician (MD, DO or PharmD) before launch. Every number is checked against its source. Drug facts are re-checked quarterly, prices monthly and whenever a label changes. How we review · Report an error